The severe global drug resistance should limit the abuse of 5 billion cefoperazone and sulbactam!

On August 25, 2021, Hunan Province issued the 2021 version of the Antimicrobial Drug Classification Management Directory.
Up to now, the latest version of the antibiotic management directory has been issued in more than ten provinces, including Shanghai, Henan, Tianjin, Gansu and other provinces
.
On August 25, 2021, Hunan Province issued the 2021 version of the Antimicrobial Drug Classification Management Directory.
Up to now, the latest version of the antibiotic management directory has been issued in more than ten provinces, including Shanghai, Henan, Tianjin, Gansu and other provinces
.
Policy management of domestic antibiotic drugs Policy management of domestic antibiotic drugs Policy management of domestic antibiotic drugs
According to factors such as the safety, efficacy, bacterial resistance and price of the antibacterial drugs, antibacterial drugs are divided into three levels: unrestricted use level, restricted use level and special use level
.
According to factors such as the safety, efficacy, bacterial resistance and price of the antibacterial drugs, antibacterial drugs are divided into three levels: unrestricted use level, restricted use level and special use level
.

Medical institutions should strictly follow relevant regulations to establish their own antibacterial drug classification management catalog and physician antibacterial drug prescription authority, and adjust them regularly, and establish a hospital-wide special use-level antimicrobial consultation expert database, and standardize the use of special-use antibacterial drugs in accordance with regulations
.
In accordance with the principle of antibacterial drug classification management, establish a management system and specific operating procedures for the selection, procurement, prescription, dispensing, clinical application and drug evaluation of antibacterial drugs
.
Medical institutions should strictly follow relevant regulations to establish their own antibacterial drug classification management catalog and physician antibacterial drug prescription authority, and adjust them regularly, and establish a hospital-wide special use-level antimicrobial consultation expert database, and standardize the use of special-use antibacterial drugs in accordance with regulations
.
In accordance with the principle of antibacterial drug classification management, establish a management system and specific operating procedures for the selection, procurement, prescription, dispensing, clinical application and drug evaluation of antibacterial drugs
.

In order to further strengthen the management of antimicrobial drugs, actively respond to microbial drug resistance, and continue to improve the level of clinical rational drug use, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance" on April 7, 2021 (the following Referred to as notice)
.
In order to further strengthen the management of antimicrobial drugs, actively respond to microbial drug resistance, and continue to improve the level of clinical rational drug use, the National Health Commission issued the "Notice on Further Strengthening the Management of Antimicrobial Drugs to Contain Drug Resistance" on April 7, 2021 (the following Referred to as notice)
.

The "Notice" is based on the current socially highly concerned microbial drug resistance problem, advocates that the overall deployment should be promoted, the management of antimicrobial drugs should be comprehensively strengthened, and the antimicrobial drug supply catalog should be scientifically adjusted and optimized; based on multidisciplinary collaboration, improve the diagnosis and treatment of infectious diseases.
priority culture with clinical pharmacists art anti-infection, regulate the β-lactams and other skin test
.
The "Notice" is based on the current socially highly concerned microbial drug resistance problem, advocates that the overall deployment should be promoted, the management of antimicrobial drugs should be comprehensively strengthened, and the antimicrobial drug supply catalog should be scientifically adjusted and optimized; based on multidisciplinary collaboration, improve the diagnosis and treatment of infectious diseases.
priority culture with clinical pharmacists art anti-infection, regulate the β-lactams and other skin test
.

The antibiotic king of 5 billion every year : cefoperazone and sulbactam The antibiotic king of 5 billion every year : cefoperazone and sulbactam The antibiotic king of 5 billion every year: cefoperazone and sulbactam
In recent years, China, Europe and the United States have accelerated the approval of new drugs, encouraging the development and marketing of new anti-drug-resistant bacteria drugs
.
In the past ten years, the Chinese government and the Food and Drug Administration have also approved the marketing of a variety of anti-drug resistant antibiotics, including compound antibiotics, and have gradually standardized the rational use of antibiotics to cope with the clinical drug resistance rate
.
In recent years, China, Europe and the United States have accelerated the approval of new drugs, encouraging the development and marketing of new anti-drug-resistant bacteria drugs
.
In the past ten years, the Chinese government and the Food and Drug Administration have also approved the marketing of a variety of anti-drug resistant antibiotics, including compound antibiotics, and have gradually standardized the rational use of antibiotics to cope with the clinical drug resistance rate
.

However, none of the antibiotics currently sold in China have completed all drug susceptibility tests in China, including the most widely clinically used compound antibiotic drugs such as cefoperazone and sulbactam, piperacillin and tazobactam.
China’s annual sales exceed RMB 5 billion, and its clinical application is extremely extensive, and it has actually involved long-term abuse.
As a result, the drug resistance rate of cefoperazone sodium and sulbactam sodium for injection has reached more than 50%, which is practically scientifically ineffective
.
However, none of the antibiotics currently sold in China have completed all drug susceptibility tests in China, including the most widely clinically used compound antibiotic drugs such as cefoperazone and sulbactam, piperacillin and tazobactam.
China’s annual sales exceed RMB 5 billion, and its clinical application is extremely extensive, and it has actually involved long-term abuse.
As a result, the drug resistance rate of cefoperazone sodium and sulbactam sodium for injection has reached more than 50%, which is practically scientifically ineffective
.

In 2014, the market size of Pfizer's "Cefoperazone and Sulbactam 1:1" (trade name: Supushen) ranked third in the cephalosporin antibiotic market, and the first in the cephalosporin compound preparation market, with a market size of 4.
515 billion.
Yuan
.
In 2014, the market size of Pfizer's "Cefoperazone and Sulbactam 1:1" (trade name: Supushen) ranked third in the cephalosporin antibiotic market, and the first in the cephalosporin compound preparation market, with a market size of 4.
515 billion.
Yuan
.

The U.
S.
FDA revokes the approval number of Cefoperazone Sodium for Injection.
The U.
S.
FDA revokes the approval number of Cefoperazone Sodium for Injection.

Cefoperazone is a third-generation cephalosporin antibiotic.
It was first marketed in the United States by Pfizer Pharmaceuticals in 1982
.
With the long-term and large-scale clinical application of cefoperazone, the resistance of bacteria to cefoperazone has become increasingly serious
.
Cefoperazone has poor stability to most β-lactamases and will be hydrolyzed by β-lactamases to varying degrees.
The unilateral registration number has been revoked by the FDA in the United States and withdrawn from the US market
.
Cefoperazone is a third-generation cephalosporin antibiotic.
It was first marketed in the United States by Pfizer Pharmaceuticals in 1982
.
With the long-term and large-scale clinical application of cefoperazone, the resistance of bacteria to cefoperazone has become increasingly serious
.
Cefoperazone has poor stability to most β-lactamases and will be hydrolyzed by β-lactamases to varying degrees.
The unilateral registration number has been revoked by the US FDA and withdrawn from the US market
.
Cefoperazone is a third-generation cephalosporin antibiotic.
It was first marketed in the United States by Pfizer Pharmaceuticals in 1982
.
The unilateral has already been revoked its registration number by the FDA in the United States and has withdrawn from the US market
.

It is worth noting that cefoperazone sodium and sulbactam sodium for injection have not been approved by the FDA for marketing in the United States due to hemolytic side effects, inability to penetrate the blood-brain barrier, and poor stability
.
It is worth noting that cefoperazone sodium and sulbactam sodium for injection have not been approved by the FDA for marketing in the United States due to hemolytic side effects, inability to penetrate the blood-brain barrier, and poor stability
.
It is worth noting that cefoperazone sodium and sulbactam sodium for injection have not been approved by the FDA for marketing in the United States due to hemolytic side effects, inability to penetrate the blood-brain barrier, and poor stability
.

Adverse reactions of cefoperazone and sulbactam Adverse reactions of cefoperazone and sulbactam Adverse reactions of cefoperazone and sulbactam
Common adverse reactions of cefoperazone and sulbactam include allergic reactions, abnormal blood coagulation, disulfiram-like reactions, liver and kidney damage, and abnormal blood sugar
.
As early as 2009, cefoperazone and sulbactam was named by China's SFDA and included in the key monitoring list of adverse drug reactions
.
Common adverse reactions of cefoperazone and sulbactam include allergic reactions, abnormal blood coagulation, disulfiram-like reactions, liver and kidney damage, and abnormal blood sugar
.
As early as 2009, cefoperazone and sulbactam was named by China's SFDA and included in the key monitoring list of adverse drug reactions
.

In recent years, reports of abnormal blood coagulation caused by cefoperazone and sulbactam are not uncommon.
The National Medical Products Administration Announcement No.
13 of 2019 requires the revision of the drug inserts containing cefoperazone, and increases thrombocytopenia and hypothrombin under adverse reactions.
For the content of original blood disease, coagulation disorder, and bleeding, the warning items about coagulation disorder and bleeding risk are added at the beginning of the item of precautions
.
In addition, the influencing factors of coagulation dysfunction caused by cefoperazone and sulbactam are related to the patient's age, nutritional status, liver and kidney dysfunction, as well as drug dosage and combination medication
.
In recent years, reports of abnormal blood coagulation caused by cefoperazone and sulbactam are not uncommon.
The National Medical Products Administration Announcement No.
13 of 2019 requires the revision of the drug inserts containing cefoperazone, and increases thrombocytopenia and hypothrombin under adverse reactions.
For the content of original blood disease, coagulation disorder, and bleeding, the warning items about coagulation disorder and bleeding risk are added at the beginning of the item of precautions
.
In addition, the influencing factors of coagulation dysfunction caused by cefoperazone and sulbactam are related to the patient's age, nutritional status, liver and kidney dysfunction, as well as drug dosage and combination medication
.
There are reports in the literature that the adverse reaction rate of cefoperazone and sulbactam is as high as 30%
.
In addition, there are clinical reports that cefoperazone and sulbactam cause severe coagulation abnormalities and cause bleeding death
.
There are reports in the literature that the adverse reaction rate of cefoperazone and sulbactam is as high as 30%
.
In addition, there are clinical reports that cefoperazone and sulbactam cause severe coagulation abnormalities and cause bleeding death
.

At present, China is the largest market for cefoperazone and sulbactam.
It has been used clinically for dozens of years.
Due to its special large-scale and deep product promotion every year, this variety has occupied the Chinese antibiotics list for many consecutive years.
In the forefront position, some areas have also gone from being widely used or even excessive to abuse
.
CHINET China's bacterial resistance monitoring data show that the resistance rate of Acinetobacter to cefoperazone and sulbactam has reached 43% or more
.
At present, China is the largest market for cefoperazone and sulbactam.
It has been used clinically for dozens of years.
Due to its special large-scale and deep product promotion every year, this variety has occupied the Chinese antibiotics list for many consecutive years.
In the forefront position, some areas have also gone from being widely used or even excessive to abuse
.
CHINET China's bacterial resistance monitoring data show that the resistance rate of Acinetobacter to cefoperazone and sulbactam has reached 43% or more
.
The resistance rate of Acinetobacter to cefoperazone and sulbactam has reached 43% or more
.

Antibiotic resistance is a scientific issue.
The treatment of drug-resistant infections is quickly becoming the norm.
The emergence of multi-drug-resistant bacteria in large numbers is a serious threat to human health
.
At the G20 Hangzhou Summit, the Chinese government promised to give priority and preferential support to China’s own companies to develop new anti-drug resistant antibiotics
.
According to the implementation of the IPPS new antibiotic use plan in the United States in 2020, the United States encourages clinicians to use new antibiotics for symptomatic treatment first, which can treat within the effective time window, more effectively protect lives, shorten treatment time, save treatment costs, and effectively prevent drug resistance The production of bacteria
.
Antibiotic resistance is a scientific issue.
The treatment of drug-resistant infections is quickly becoming the norm.
The emergence of multi-drug-resistant bacteria in large numbers is a serious threat to human health
.
At the G20 Hangzhou Summit, the Chinese government promised to give priority and preferential support to China’s own companies to develop new anti-drug resistant antibiotics
.
According to the implementation of the IPPS new antibiotic use plan in the United States in 2020, the United States encourages clinicians to use new antibiotics for symptomatic treatment first, which can treat within the effective time window, more effectively protect lives, shorten treatment time, save treatment costs, and effectively prevent drug resistance The production of bacteria
.

Any drug that has been used for a long time or in a large amount will develop drug resistance and or tolerance to varying degrees.
Therefore, humans need to continuously develop new drugs, especially for antibiotics that have been used in large quantities for a long time.
It’s a scientific common sense to call on the National Health Commission and Hunan Provincial Health Commission, as well as medical experts and scholars, should be based on medical science.
To effectively limit the abuse of cefoperazone sodium and sulbactam sodium for injection and piperacillin sodium and tazobactam sodium for injection, the drug resistance can be reduced by periodically adjusting the medication and reducing the use or frequency of these two drugs
.
We must not forget our original intention and the conscience of scientists! ! We must use new drugs from Chinese companies as much as possible, work together to effectively reduce the resistance of antibiotics, serve the health of the Chinese people, and effectively prevent the national public health infection and epidemic risk
.
Any drug that has been used for a long time or in a large amount will develop drug resistance and or tolerance to varying degrees.
Therefore, humans need to continuously develop new drugs, especially for antibiotics that have been used in large quantities for a long time.
It’s a scientific common sense to call on the National Health Commission and Hunan Provincial Health Commission, as well as medical experts and scholars, should be based on medical science.
To effectively limit the abuse of cefoperazone sodium and sulbactam sodium for injection and piperacillin sodium and tazobactam sodium for injection, the drug resistance can be reduced by periodically adjusting the medication and reducing the use or frequency of these two drugs
.
We must not forget our original intention and the conscience of scientists! ! We must use new drugs from Chinese companies as much as possible, work together to effectively reduce the resistance of antibiotics, serve the health of the Chinese people, and effectively prevent the national public health infection and epidemic risk
.

Trax's perfect store execution empowers pharmaceutical and health companies to tap the most growth potential in all markets around the world, and
60% of key channels increase the distribution rate! Trax injects new impetus into the channel inspection of pharmaceutical companies